Alchemab Ther­a­peu­tics

People who beat cancer, or have neurode­gen­er­a­tive conditions that are very slow to progress, may harbor naturally occurring protective antibodies that make them more resilient against these devastating diseases. Alchemab sequences the B cells of these individuals, uses AI to identify groups of related antibodies across the resilient population, finds the binding targets of these antibodies, and uses that information to design treatments that could help other patients fight solid tumors, infections, or Alzheimer’s.